Description
Trestolone, also known as 7α-methyl-19-nortestosterone (MENT), is an experimental androgen/anabolic steroid (AAS) and progestogen medication which has been under development for potential use as a form of hormonal birth control for men and in androgen replacement therapy for low testosterone levels in men but has never been marketed for medical use. It is given as an implant that is placed into fat. As trestolone acetate, an androgen ester and prodrug of trestolone, the medication can also be given by intramuscular injection.
Trestolone was first described in 1963. Subsequently, it was not studied again until 1990. Development of trestolone for potential clinical use started by 1993 and continued thereafter. No additional development appears to have been conducted since 2013. The medication was developed by the Population Council, a non-profit, non-governmental organization dedicated to reproductive health.
Trestolone Acetate, also called MENT, until recently has been flying under the radar. With the increase of availability in raw materials, usually from China, many underground labs have been producing it. Trestolone is beginning to gain popularity as more and more people are beginning to venture out and have started using it. Most of the attraction is the unheard of anabolic-androgenic ratio of this compound. On paper trestolone has a ratio of 2300-650. Which means it is 23X more andabolic than Testosterone and 6.5X more androgenic. In comparison to another very powerful steroid on paper, Trenbolone, with a anabolic-androgenic rating of 500-500 it even fails to compare to the anabolic rating of Trestolone.
